Navigation Links
Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results
Date:9/30/2010

stricted cash 11,135,880 7,325,000 Investments 168,858 879,228 Accounts receivable, net of allowance for doubtful accounts of $1,343,421 and $694,370 as of June 30, 2010 and 2009, respectively 33,195,201 19,222,707 Inventories 2,200,614 3,277,194 Other receivables 13,241 167,012 Other receivables - related parties 324,060 -- Advances to suppliers 260,688 236,496 Financing costs - current 435,634 680,303 Total current assets 156,350,911 136,154,057 PLANT AND EQUIPMENT, net 13,284,312 13,957,397 OTHER ASSETS: Long term prepayments 110,725 0 Restricted investments -- 1,033,463 Financing costs, net -- 556,365 Intangible assets, net 32,594,326 17,041,181 Total other assets 32,705,051 18,631,009 Total assets $202,340,274 $168,742,463 L I A B I L I T I E S A N D S H A R E H O L D E R S' E Q U I T Y CURRENT LIABILITIES: Accounts payable $4,113,219 $6,146,497 Short term bank loans 2,209,500 2,197,500 Notes payable 11,135,880 7,325,000 Other payables 3,888,035 2,152,063 Refundable security deposits due to distributors 3,829,800 4,102,000 Other payables - related parties 255,595 238,956 Accrued liabilities 4,899,829 1,356,898 Liabilities assumed from reorganization 524,614 1,565,036 Taxes payable 6,259,271 11,248,226 Derivative liabilities 18,497,226 -- Convertible debt, net of discount of $13,699,752 as of June 30, 2010 12,210,248 -- Total current liabilities 67,823,217 36,332,176 CONVERTIBLE DEBT, net of discount $28,493,089 as of June 30, 2009 -- 6,346,911 Total liabilities 67,823,217 42,679,087 COMMITMENTS AND CONTINGENCIES SHAREHOLDERS' EQUITY: Convertible preferred stock Series A ($0.001 par value; 20,000,000 shares authorized as of June 30, 2010 and 2009, respectively; 0 shares issued and outstanding as of June 30, 2010 and 2009) -- -- Common stock ($0.001 par value, 22,500,000 shares authorized, 11,701,802 and 10,435,099 shares issued and outstanding as of June 30, 2010 and 2009, respectively) 11,702 10,435 Paid-in-capital 30,846,915 48,397,794 Capital contribution rec
'/>"/>
SOURCE Jiangbo Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. Jiangbo Pharmaceuticals Chairman to Ring NASDAQ Opening Bell on August 27, 2010
2. Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets
3. Jiangbo Pharmaceuticals to Attend Global Hunter Securities China Conference
4. Jiangbo Pharmaceuticals Announces the Appointment of New Chief Executive Officer
5. Jiangbo Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Global Market
6. Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010
7. Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010
8. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Its Second Quarter of Fiscal Year 2010
9. Jiangbo Pharmaceuticals Osteomyelitis Treatment Tablets to be Included in Chinas National Insurance Directory
10. Jiangbo Pharmaceuticals Obtains Renewal of GMP Certificate
11. Jiangbo Pharmaceuticals Announces First Quarter Fiscal Year 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Most osteoporosis patients want a choice in ... survey* sponsored by Mission Pharmacal Company. The survey, conducted ... online support community, revealed that 74 percent of osteoporosis ... a form other than a pill or a tablet. ...
(Date:1/15/2014)... LAWRENCEVILLE, N.J. , Jan. 15, 2014  Celsion Corporation (the ... it has received commitments from institutional investors to purchase ... common stock in an at-the-market registered direct offering, led ... Company entered into definitive purchase agreements with these investors ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... Phase III Studies With Ofatumumab, Zalutumumab and Zanolimumab, ... (OMX:,GEN) reports today that the last patient to ... in the pivotal Phase III clinical trial,of ofatumumab ... received the last scheduled treatment., In order ...
... Company to Host Conference Call/Webcast at 8:30 a.m. ... May 28 Alfacell Corporation,(Nasdaq: ACEL ) ... from its confirmatory Phase IIIb clinical trial of ... significance for the,primary endpoint of survival in unresectable ...
Cached Medicine Technology:Genmab Announces Updates on Phase III Cancer Studies 2Genmab Announces Updates on Phase III Cancer Studies 3Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial 2Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial 3Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial 4Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial 5
(Date:7/9/2014)... been a sharp increase in the number of cancer ... online, interactive service that allows patients to view laboratory ... appointments, and renew prescriptions. , Over a six-year period, ... each year increased five-fold, while the number of total ... a study by Dr. David Gerber , Associate ...
(Date:7/9/2014)... of flatulence and have a reputation for being highly toxic, ... is now being being found to offer potential health benefits ... attacks and dementia. A new compound (AP39), designed and made ... future therapies, by targeting delivery of very small amounts of ... , Scientists in Exeter have already found that the ...
(Date:7/9/2014)... printing on prescription labels handed out by pharmacists ... in taking medication, according to new research by ... Institute for the Blind)., The study, published recently ... that labels on prescription medications dispensed by pharmacies ... legibility. , By simply following recommended guidelines for ...
(Date:7/9/2014)... diseases has risen dramatically in Western societies. One frequently ... microorganisms and have fewer infections than previous generations, thereby ... by researchers at Sahlgrenska Academy, University of Gothenburg, monitored ... of the immune system in relation to allergic disease. ... the Vstra Gtaland Region, half of them on farms ...
(Date:7/8/2014)... Defense Advanced Research Projects Agency (DARPA) awarded Lawrence ... to develop an implantable neural device with the ... brain to help restore memory, DARPA officials announced ... understanding that memory is a process in which ... information, store it and retrieve it. Certain types ...
Breaking Medicine News(10 mins):Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 3
... Calif., March 10 ISTA Pharmaceuticals, Inc. (Nasdaq: ... the Cowen and Company 29th Annual Health Care Conference ... 2009, in Boston, MA.ISTA,s President and Chief Executive Officer, ... the Company,s commercial and clinical progress. To access the ...
... 10 Orthocrat, Ltd. announced today that OAD ... OrthoFlow workflow solution. OrthoFlow is designed to save ... exam room to exam room, seeing large volumes of patients ... simply swipes his badge over a reader, and the images ...
... Sahlgrenska Academy, University of Gothenburg, Sweden, shows that three genes ... normally involved in several fundamental processes in the cell. This ... life and principally affect children and young people. , A ... investigated in the work presented in the thesis. This family ...
... Waterlase(TM), DIAGNOdent Laser Technology and the First Comprehensive Dental ... Area residents now have access to the latest ... all in a luxurious spa environment designed for relaxation ... and general dentist, designed her first Northern Westchester location, ...
... The Pew Charitable Trusts today announced that Susan G. Komen ... space in its D.C. headquarters, located at 901 E Street, ... Fenty, Pew has dedicated the vast majority of its building ... first "nonprofit village.""Susan G. Komen for the Cure(R) has been ...
... Health Plan Members Drop Coverage for Multiple Reasons; ... Necessary to Reduce Disenrollment and Improve Balance SheetORLANDO, ... behalf of ConnextionsHealth provides both good and bad ... properly managing member disenrollment delivers a significant, positive ...
Cached Medicine News:Health News:'Swipe Card, See Image': OAD Orthopaedics Improves Clinical Workflow with OrthoFlow 2Health News:Rearrangements of multifunctional genes cause cancer in children and young people 2Health News:High-Tech Meets Luxury at New Dental Practice: Introducing Westchester Smile Design 2Health News:Susan G. Komen for the Cure(R) Signs Lease at Pew's Nonprofit Village 2Health News:Susan G. Komen for the Cure(R) Signs Lease at Pew's Nonprofit Village 3Health News:Common Approaches to Member Retention by Health Insurance Plans are Ineffective, New Study Shows 2Health News:Common Approaches to Member Retention by Health Insurance Plans are Ineffective, New Study Shows 3
... generation of Urocap, features automatic ... stopping and printing. The advanced ... with superior low flow rate ... ICS nomenclature normative comparisons to ...
... Stents combine a unique polymer material that ... shape with a chemically bonded wettable solution ... is a stent that satisfies the need ... Lubri-Flex® is available in a wide variety ...
... The Pathfinder Chlamydia Culture ... reliable staining of intracellular ... reticulate bodies) in tissue ... antibody used in this ...
... a direct antigen detection system, that can use ... and monoclonal antibodies to detect RSV directly in ... and reproducibility of monoclonal antibodies with the speed ... are availalbe within 90 minutes. The Pathfinder RSV ...
Medicine Products: